Xeris Biopharma Holdings (XERS) Stock Analysis & Winston Score

Xeris Biopharma is a specialty pharmaceutical company that makes ready-to-use injectable medicines for people with serious hormonal and metabolic conditions. Its main products include Gvoke, a glucagon rescue pen for people with diabetes who experience dangerously low blood sugar, and Recorlev, a treatment for Cushing's syndrome, a rare hormonal disorder. The company also sells Ogluo, a glucagon product marketed in Europe. Xeris earns money by selling these prescription drugs directly to patients through pharmacies and specialty distributors, primarily in the United States and the United Kingdom. The company is relatively small, with annual revenues in the low hundreds of millions of dollars, and its edge comes from proprietary formulation technology that keeps certain drugs stable in liquid form without refrigeration. The key risk is that Xeris carries significant debt and must grow its commercial products fast enough to reach profitability, which remains a challenge for small specialty pharma companies competing against larger, better-funded rivals.